Open AccessDigoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF ‐ TIMI 48 Trial
Author(s) -
Eisen Alon,
Ruff Christian T.,
Braunwald Eugene,
Hamershock Rose A.,
Lewis Basil S.,
Hassager Christian,
Chao TzeFan,
Le Heuzey Jean Yves,
Mercuri Michele,
Rutman Howard,
Antman Elliott M.,
Giugliano Robert P.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.006035
Subject(s) - medicine , atrial fibrillation , cardiology , digoxin , heart failure , hazard ratio , ejection fraction , timi , myocardial infarction , cardiogenic shock , stroke (engine) , thrombolysis , confidence interval , mechanical engineering , engineering
Digoxin is widely used in patients with atrial fibrillation despite the lack of randomized controlled trials. Observational studies report conflicting results regarding its association with mortality, perhaps because of residual confounding by the presence of heart failure (HF).